Sanofi: Information concerning the total number of voting rights and shares - December 2025GlobeNewsWire • 01/14/26
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with SanofiGlobeNewsWire • 01/12/26
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetesGlobeNewsWire • 01/12/26
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistenceGlobeNewsWire • 01/07/26
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing CapabilitiesGlobeNewsWire • 01/06/26
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young ChildrenZacks Investment Research • 01/05/26
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetesGlobeNewsWire • 01/05/26
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAXPRNewsWire • 12/31/25
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis DrugZacks Investment Research • 12/24/25
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipelineGlobeNewsWire • 12/24/25
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisGlobeNewsWire • 12/24/25
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaGlobeNewsWire • 12/23/25
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaGlobeNewsWire • 12/23/25
Sanofi: Information concerning the total number of voting rights and shares - November 2025GlobeNewsWire • 12/22/25